Restricting the selection of antibiotic-resistant mutants: A general strategy derived from fluoroquinolone studies

Clinical Infectious Diseases

Volumn 33, Issue SUPPL. 3, 2001, Pages

  Zhao, X ^a   Drlica, K ^a  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; BACTERIAL DNA; CHLORAMPHENICOL; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; ISONIAZID; MICONAZOLE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RIFATER; SULTAMICILLIN; TETRACYCLINE; TIMENTIN; TOBRAMYCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIUM MUTANT; CAMPYLOBACTER; CANDIDA GLABRATA; CONCENTRATION RESPONSE; CONFERENCE PAPER; DRUG STRUCTURE; ESCHERICHIA COLI; GROWTH INHIBITION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MUTANT PREVENTION CONCENTRATION; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; VETERINARY MEDICINE;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FLUOROQUINOLONES; HUMANS; MUTAGENESIS;

EID: 0035884924     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/321841     Document Type: Conference Paper

References (45)

1. The epidemiology of bacterial resistance to antimicrobial agents
2. Multidrug resistance: A sign of the times
3. Development of resistance during antibiotic therapy
4. Staphylococcus aureus: A well-armed pathogen
5. The emergence of drug-resistant tuberculosis in New York City
6. Trends in the susceptibility of tuberculosis in New York City, 1987-1991
7. Origin and interstate spread of a New York City multidrug resistant Mycobacterium tuberculosis clone family: Adverse implications for tuberculosis control in the 21st century
8. Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug resistant Mycobacterium tuberculosis
9. First-line tuberculosis therapy and drug-resistant Mycobacterium tuberculosis in prisons
10. Ciprofloxacin resistant Campylobacter spp. in humans: An epidemiological and laboratory study
11. Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998
12. Quinolone resistance in Campylobacter isolated from man and poultry following the introduction of fluoroquinolones in veterinary medicine
13. Emergence and dissemination of quinolone-resistant Escherichia coli in the community
14. Bacterial mutagenicity and the 4-quinolones
15. Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates
16. DNA gyrase, topoisomerase IV, and the 4-quinolones
17. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: Selective targeting of gyrase or topoisomerase IV by quinolones
18. Primary targets of fluoroquinolones in Streptococcus pneumoniae
19. Fluoroquinolone action against mycobacteria: Effects of C8 substituents on bacterial growth, survival, and resistance
20. Selection of antibiotic resistance: Allelic diversity among fluoroquinolone-resistant mutations
21. DNA topoisomerase targets of the fluoroquinolones: A strategy for avoiding bacterial resistance
22. Killing of Staphylococcus aureus by C8-methoxy fluoroquinolones
23. Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: Effects of a C8-methoxyl group on survival in liquid media and in human macrophages
24. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus
25. Mutant prevention concentration (MPC) as a measure of fluoroquinolone potency against mycobacteria
26. Bacterial counts in cerebrospinal fluid of children with meningitis
27. Concentrations of bacteria in cerebrospinal fluid of patients with bacterial meningitis
28. Drug resistance in mycobacteria
29. Mutant prevention concentration (MPC) as a guide for treating Streptococcus pneumoniae with fluoroquinolones
30. Strategies to minimize the development of antibiotic resistance
31. Resistance to quinolones in Gram-negative microorganisms: Mechanisms and prevention
32. Mutant prevention concentration as a measure of antibiotic potency: Studies with clinical isolates of Mycobacterium tuberculosis
33. Fixed-dose combinations of antituberculous medications to prevent drug resistance
34. Comparative trial of isoniazid alone in low high dosage isoniazid plus PAS in the treatment of acute pulmonary tuberculosis in East Africa
35. Emergence of MDR TB during standard therapy in AIDS
36. Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis
37. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid
38. Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. II. Two-month, daily administration study
39. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages
40. Determination of drug susceptibility of mycobacteria to pyrazinamide in 7H10 agar
41. Pyrazinamide
42. Association between early inhibition of DNA synthesis and the MICs and MBCs of carboxyquinolone antimicrobial agents for wild-type and mutant [gyrA nfxB(ompF) acrA] Escherichia coli K-12
43. Mechanism of fluoroquinolone action
44. Gatifloxacin activity against quinolone-resistant gyrase: Allele-specific enhancement of bacteriostatic and bactericidal activity by the C8-methoxy group
45. Reasons for the emergence of antibiotic resistance